The role of GABAB receptors in the vestibular oculomotor system in mice

Behavioural Brain Research
N ShimizuT Makishima

Abstract

Systemic administration of a gamma-amino butyric acid type B (GABAB) receptor agonist, baclofen, affects various physiological and psychological processes. To date, the effects on oculomotor system have been well characterized in primates, however those in mice have not been explored. In this study, we investigated the effects of baclofen focusing on vestibular-related eye movements. Two rotational paradigms, i.e. sinusoidal rotation and counter rotation were employed to stimulate semicircular canals and otolith organs in the inner ear. Experimental conditions (dosage, routes and onset of recording) were determined based on the prior studies exploring the behavioral effects of baclofen in mice. With an increase in dosage, both canal and otolith induced ocular responses were gradually affected. There was a clear distinction in the drug sensitivity showing that eye movements derived from direct vestibulo-ocular reflex pathways were relatively unaltered, while the responses through higher-order neural networks in the vestibular system were substantially decreased. These findings were consistent with those observed in primates suggesting a well-conserved role of GABAB receptors in the oculomotor system across frontal-eyed and later...Continue Reading

References

Apr 2, 1979·Experimental Brain Research·T RaphanB Cohen
Jan 1, 1992·Experimental Brain Research·M B DutiaD S McQueen
Jan 1, 1988·Experimental Brain Research·C Darlot, P Denise
Jan 1, 1986·Biological cybernetics·T C Hain
Dec 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·V Chan-PalayT L O'Donohue
Mar 1, 1995·General Pharmacology·R E HumeniukJ M White
Mar 1, 1996·Experimental Brain Research·G A Bush, F A Miles
Jun 1, 1997·Genes and Function·S K KoekkoekC I De Zeeuw
Jun 19, 2002·Experimental Brain Research·Theodore Raphan, Bernard Cohen
Oct 1, 1990·The European Journal of Neuroscience·B. J. M. Hess, N. Dieringer
Nov 9, 2002·Journal of Neurophysiology·Keisuke KushiroTheodore Raphan
Dec 10, 2003·Annals of the New York Academy of Sciences·Bernard CohenTheodore Raphan
Dec 13, 2005·Journal of Neurophysiology·John S StahlChris I De Zeeuw
Dec 13, 2005·Experimental Brain Research·Mingjia DaiBernard Cohen
May 24, 2006·Journal of the Association for Research in Otolaryngology : JARO·Daniel R Calabrese, Timothy E Hullar
Jul 22, 2006·Nature Reviews. Neuroscience·Bruce L McNaughtonMay-Britt Moser
Apr 10, 2007·Alcohol·Agnieszka KorkoszPrzemyslaw Bienkowski
Jun 15, 2007·Experimental Brain Research·Scott J WoodGilles Clément
Sep 8, 2007·Behavioural Brain Research·Allan V KalueffAndrew J Griffith
Mar 15, 2008·Annual Review of Neuroscience·Dora E Angelaki, Kathleen E Cullen
Jun 11, 2010·Experimental Brain Research·Mingjia DaiBernard Cohen
Feb 5, 2011·Experimental Brain Research·Jean Laurens, Dora E Angelaki
Oct 13, 2011·BMC Neuroscience·Tomoko MakishimaScott Wood
Jul 28, 2012·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Robert W StackmanSidney B Williams
May 1, 2013·Acta Oto-laryngologica·Aurelie P WeertsFloris L Wuyts
Jun 26, 2014·Experimental Brain Research·James R Lackner
Apr 2, 2015·Experimental Brain Research·Patrick A ArmstrongTomoko Makishima

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.